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Abstract: Seventy-two patients undergoing allogeneic
transplantation were treated with voriconazole (VOR) as antifungal
prophylaxis starting from day  2 of transplantation and continuing
until withdrawal of immunosuppression. Patients were assessed for
safety and the incidence of de¢nite, probable, or possible fungal
infection throughout transplantation was evaluated.VOR was well
tolerated. Only 14% of patients required interruption of VOR therapy
because of toxicity: liver toxicity (8%), cardiac Q^T interval
prolongation (1%), or other side e¡ects (5%). In the early post-
transplant period (o120 days), only 2 patients developed invasive
fungal infection: 1 mucormycosis infection and 1 disseminated
Aspergillus infection. In the late post-transplant period (4120 days), no
patients developed probable or de¢nite fungal infectionwhile receiving
VOR. No Candida infections were seen in either period.These data
suggest that fungal prophylaxis withVOR following allogeneic







































































































Invasive fungal infection (IFI) remains a signi¢cant cause
of morbidity and mortality following allogeneic hemato-
poietic stem cell transplantation (alloSCT). Fluconazole
(FLU) is widely used as antifungal prophylaxis in patients
undergoing alloSCT. In randomized trials, FLU prophy-
laxis has decreased the incidence of IFIs and reduced the
need for amphotericin therapy (1^3). In addition, long-term
data have demonstrated a survival advantage for patients
receiving FLU versus placebo following bone marrow
transplant (3). However, FLU has a narrow antifungal spec-
trum and resistant Candida and ¢lamentous mold infec-
tions remain problematic. In a recent randomized trial,
posaconazole, a second-generation triazole with broad-
spectrum activity against yeasts and molds, has demon-
strated improved e⁄cacy over FLU as prophylaxis for
invasiveAspergillus infection in patients with severe graft-
versus-host disease (GVHD) following alloSCT (4). Limita-
tions of posaconazole include the lack of an intravenous
(IV) formulation and poor bioavailability. Voriconazole
(VOR) is another second-generation triazole with improved
activity against IFIs including non-albicans Candida and
Aspergillus species (5).VOR is available in both oral and IV
formulations, has excellent bioavailability, and conse-
quently is an attractive alternative to FLU and posacona-
zole for prophylaxis following alloSCT.
Since approval by the US Food and Drug Administration
in 2001,VOR has been used as standard antifungal prophy-
laxis for patients undergoing alloSCTat the University of
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California, San Francisco (UCSF) Medical Center. In this
retrospective review, we report the incidence of early and
late IFIs and assess the toxicity of VOR when used as pro-
phylaxis for alloSCT. All patients have been followed for
41year after alloSCT, with a mean follow-up of 1.83 years.
Material and methods
Patient selection
The study design was a retrospective chart review of con-
secutive patients undergoing alloSCT at UCSF Medical
Center from May 2002 through June 2004. Patients received
VOR as antifungal prophylaxis and the frequency of IFI
was determined. Seventy-two patients were included in
this analysis and no patients were excluded due to early
mortality (death within 30 days of alloSCT). All patients
signed informed consent for the transplant procedure and
approval was obtained for this retrospective analysis from
the UCSF institutional review board.
Transplantation and supportive care
Both myeloablative and non-myeloablative conditioning
regimens were utilized. Myeloablative therapy consisted
of IV busulfan (12.8 mg/kg) or total body irradiation
(1200 cGy) with £udarabine (150 mg/m2) or cyclophos-
phamide (120 mg/kg). Non-myeloablative therapy utilized
IV busulfan at a lower dose (4.8^6.4 mg/kg), or melphalan
(100 mg/m2) with £udarabine. Anti-thymocyte globulin
was added for non-myeloablative alloSCT with unrelated
donors. In general, GVHD prophylaxis consisted of tacroli-
mus (TAC) starting from day  2 with a target level of
5^15 ng/mL and methotrexate (5 mg/m2 IV once daily on
days 11, 13, 16, and 111). Patients receiving non-
myeloablative unrelated alloSCTalso received mycopheno-
late mofetil (15 mg/kg twice daily [b.i.d.]) starting from day 0
and continuing until day 160. Most patients received gran-
ulocyte colony-stimulating factor (G-CSF) mobilized periph-
eral blood stem cells, with a target dose of 5  106/kg
recipient weight. Human leukocyte antigen (HLA) typing
was performed using high-resolution molecular techniques
for unrelated donors and only well-matched donors were
utilized (i.e., siblings were fully HLA-matched while unre-
lated donors were matched at 7/8 or 8/8 HLA-loci [A, B, C,
DR] for myeloablative SCT, or 9/10, or 10/10 HLA-loci [A, B,
C, DR, and DQ] for non-myeloablative SCT). Stem cell pro-
cessing was performed for ABO incompatibility according
to standard blood banking procedures. By convention, the
day of stem cell infusion was considered day 0 of alloSCT.
Patients were hospitalized in single rooms equippedwith
high-e⁄ciency particulate air (HEPA) ¢lter systems. Infec-
tious disease prophylaxis included oral antibacterials
(levo£oxacin or moxi£oxacin) during neutropenia, oral or
IV antivirals starting from day  2 (acyclovir), and pro-
phylaxis for Pneumocystis jirovecii pneumonia following
engraftment (i.e., trimethoprim/sulfamethoxazole or dap-
sone). Oral VOR 4mg/kg b.i.d. started from day  2 and
continued until immunosuppression was discontinued
(4100 days).Weight-basedVOR dosing was chosen to limit
intra-patient variability and in an attempt to improve ther-
apeutic drug delivery. Broad-spectrum IVantibiotics were
used for episodes of febrile neutropenia. Preemptive moni-
toring of cytomegalovirus (CMV) infection (weekly CMV
blood antigen) was used for patients who were at risk for
CMVreactivation. G-CSF was given to all patients starting
at day 17 and continued until absolute neutrophil count
41500/mL for 2 consecutive days. Corticosteroids were
used as ¢rst-line therapy for acute and chronic GVHD.
Evaluations and de¢nitions
The primary objective of the study was to evaluate the in-
cidence of early and late IFI usingVOR as prophylaxis for
alloSCT. IFI was evaluated according to EORTC-de¢ned
criteria (Fig. 1) (6). Brie£y, de¢nite IFI was de¢ned as a fun-
gal pathogen isolated by culture or identi¢ed by histology
from a known sterile site (i.e., biopsy-proven disease); prob-
able IFI included episodes with clinical evidence of disease
(abnormal chest x-ray) and positive culture from the site
(e.g., bronchoalveolar lavage, sputum) or positive galac-
tomannan assay. Possible IFI included episodes with an ab-
normal radiology study plus 2 or more abnormal host fac-
tors (e.g., fever, sputum, cough) but no positive cultures.
Plasma VOR drug levels and galactomannan assays were
not routinely performed. Early IFI was de¢ned as that
Definite IFI: histopathologic or cytopathologic evidence of hyphae or 
yeast, or positive culture result on sample obtaind by sterile procedure
from a normally sterile and clinically or radiologically abnormal site 
consistent with infection. 
Probable IFI: one host factor (i.e., persistent fever, prolonged 
neutropenia, steroid use, graft-versus-host disease) AND one 
microbiologic criteria (i.e., positive culture of sputum/broncho-alveolar  
lavage or positive serum galactomannan antigen assay) AND one major 
(classic computerized tomography finding) or two minor clinical criteria 
(e.g., cough, hemoptysis, pleural rub, new infiltrate). 
Possible IFI: one host factor AND one microbiologic criteria or one 
major/two minor clinical criteria .
Fig. 1. EORTC/NIAID criteria for possible, probable, and de¢nite inva-
sive fungal infections (IFIs) (6).
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occurring within 120 days of alloSCT, with late IFI occur-
ring after day120. All microbiologic and radiographic data
for each patient were reviewed.
Secondary outcomes assessedwere incidence of non-fun-
gal infections, incidence of acute/chronic GVHD, VOR-re-
lated toxicity, treatment-related mortality, disease-free
survival, and overall survival.Treatment-related mortality
was de¢ned as any non-disease-associated death occurring
within 120 days of alloSCT.
Results
Subjects had a wide variety of malignant disease (Table 1).
Approximately half of the patients received non-myeloabla-
tive conditioning and a slight majority of patients received
stem cells from sibling donors. In general, most patients
were considered high-risk because of adverse cytogenetics,
prior disease relapse, or failure of prior autologous trans-
plantation. The mean follow-up for survivors is 668 days
(1.83 years, range 0.10^4.23 years) after alloSCT.
Primary endpoint
Seventy-two patients were evaluated for early IFI and only
2 developed de¢nite IFI (Table 2). One patient developed IFI
following severe GVHD requiring treatment with more
than 3 immunosuppressive agents.This patient was hospi-
talized continuously post alloSCTand died of IFI with ac-
tive GVHD at approximately day 1100 post alloSCT.
Disseminated mucormycosis infectionwas identi¢ed at au-
topsy.The second patient developed veno-occlusive disease
within 25 days following alloSCT and discontinued VOR
because of elevated total bilirubin at approximately day 30
post transplant. This patient subsequently received an
echinocandin for antifungal prophylaxis and developed
IFI with Aspergillus and Scedosporium proli¢cans. The pa-
tient died of IFI at approximately day 80 post alloSCT.
No cases of probable IFI were identi¢ed and 6 cases of
possible IFI occurred. Five of the patients with possible
IFI responded to either broad-spectrum antibiotics or the
addition of an echinocandin to VOR therapy. One patient
died rapidly from pneumonia and culture-negative sepsis,
presumably of bacterial origin. In general, all patients with
possible IFI were more likely to have viral or bacterial etiol-
ogies for their infections.
Sixty-four patients survived longer than 120 days post
transplantation and thus were evaluable for incidence of
late IFI. Late IFI developed only in patients who had
chronic GVHD, or who were on steroids for other reasons
(relapse, possible autoimmune cytopenia).Two patients de-
veloped de¢nite IFI (bothAspergillus) and both died of pro-
gressive infection. Both patients had been o¡ VOR for
several months before development of IFI (1 due to hyper-
bilirubinemia, 1 who was non-adherent with VOR prophy-
laxis despite chronic GVHD). The 4 patients experiencing
late probable IFI also were already o¡ VOR at the time of
Patient characteristics (n572)











Acute myelogenous leukemia 16
Acute lymphocytic leukemia 9
Myeloma/plasmacytoma 8
Myelodysplasia 7
Chronic myelogenous leukemia 5
Chronic lymphocytic leukemia 4
Hodgkin’s disease 3
Myeloproliferative disorders 2





Matched sib (PBSC/BM) 37 (36/1)
Matched unrelated (PBSC/BM) 35 (24/11)
Prep, preparative regimen; Stem cell, stem cell source; PBSC, peripheral
blood stem cells; BM, bone marrow cells; sib, sibling.
Table1





De¢nite (%) 2 patients (3%) 2 patients (3%)
Probable (%) 0 patients (0%) 4 patients (6%)
Possible (%) 6 patients (8%) 6 patients (9%)
Table 2
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their fungal infection. The patients with possible late IFI
had presumed non-fungal origin of their infections. No pa-
tients receivingVOR for fungal prophylaxis later than day
120 post alloSCTdeveloped probable or de¢nitive late IFI.
Overall, no cases of invasive candidal infection occurred
in either the early or late periods. One case of zygomycosis
was identi¢ed.
Secondary endpoints
VOR was well tolerated. Ten patients (14%) stopped VOR
because of drug toxicity.The reasons for stopping included
elevated liver function tests (LFT) in 6 patients, veno-occlu-
sive disease in 2 patients, toxic TAC level in 1 patient, and
prolonged cardiac corrected Q-T interval (QTc) (4500
msec) in 1 patient. Four patients were able to restart VOR
when their LFTabnormalities improved. Of note, VOR in-
creased serum TAC levels in all patients, necessitating a
60% reduction in standard TAC dosing. Despite a low inci-
dence of fungal disease, bacterial and viral infections were
common (Table 3). The incidence of CMV reactivation was
approximately 28% and gram-positive bacteremia was
24% in the early post-transplant period. Late post-trans-
plant gram-positive bacteremiawas seen in 35%of patients
and late CMV re-activation occurred in approximately 10%
of patients. Clostridium di⁄cile infections were detected in
11/72 (15%) of early patients and 7/64 (11%) of late patients,
and was more prevalent than expected.
The incidence of acute and chronic GVHD was 34% and
61%, respectively (Table 4). Severe (Grades III^IV) acute
GVHD was seen in 11% of patients.Treatment-related mor-
tality within the ¢rst 120 days of transplant was 11% and
within the ¢rst year was 21%. Approximately 6% of pa-
tients died of GVHD and 14% died directly due to infection
(3% IFI, 11% bacterial infection). The 2-year progression-
free survival and overall survival rates in this high-risk
populationwere 38%and 47%, respectively (Fig. 2). Disease
relapse was the most common cause of death (19 patients;
30%).
Discussion
The main focus of this retrospective review was to evaluate
the safety and e⁄cacyof VOR as prophylaxis for IFI follow-
ing alloSCT. Epidemiology studies suggest that there is a

















Viral HSV/VZV 3 5
CMV antigen 28 9
CMV disease 0 1
Resp viruses 5 14
Total 36 29
Mycobacterial 0 2
post SCT, post stem cell transplant; Gram1 , gram-positive organism;
GNR, gram-negative rod; C. di¡.,Clostridium di⁄cile; GI, gastrointestinal;
















Fig. 2. Kaplan^Meier curve showing treatment-related mortality (TRM)
and overall survival (OS).
Incidence of acute and chronic graft-versus-host disease
T|ming Extent No. of patients (%)
Acute Grade I 8 (11%)
Grades II^IV 16 (23%)
Total 24 (34%)
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bimodal incidence of IFI following alloSCT (7, 8).The initial
peak incidence is during marrow aplasia, when neu-
tropenia is severe and barrier breakdown is present (day
o40). Although mold infections predominate, Candida in-
fections also occur. The second peak occurs following day
40 but usually 4day 100 with the development of chronic
GVHD. Invasive mold and Candida infections occur.The in-
cidence of early IFI has been reported to be approximately
4% (7 ).The incidence of late fungal infection is not well re-
ported but generally believed to occur in an additional 10^
15% of patients surviving4120 days post alloSCT (9, 10).
Our data suggest that antifungal prophylaxis withVOR
in the setting of alloSCT is both safe and e¡ective. Only 2 of
72 patients developed early IFI (1while onVOR), an accept-
able rate (2.8%) of IFI (meets 95% con¢dence interval [CI]
assuming an expected IFI rate of 4% [CI 1.88^2.88]). This
low incidence of early mold infection con¢rms 2 prior stud-
ies of VOR prophylaxis in alloSCT reported by Siwek et al.
(11) and Tri¢lio et al. (12). Both studies reported a low inci-
dence of mold infections but a higher incidence of break-
through Candida and zygomycosis infections. The Tri¢lio
study limited VOR prophylaxis to high-risk alloSCT pa-
tients (i.e., those taking corticosteroids or with active
GVHD). Overall, they reported 6 invasive Candida infec-
tions (incidence 10%), with Candida glabrata being the
most common isolate. Of note, C. glabrata has a high mini-
mum inhibitory concentration for 90% of organisms
(  1mcg/mL) withVOR, and several patients in the study
had low serumVOR levels.The study used oralVOR dosing
of 200 mg b.i.d. and the authors subsequently identi¢ed
plasma concentrations of VORo2 mcg/mL as a risk factor
for IFI, especially Candida. In our study, the mean oralVOR
dose was 300 mg b.i.d. It is well established that plasma
concentrations are exponentially correlated to dose, there-
by an increase fromVOR 200 to 300 mg b.i.d. is expected to
increase plasma VOR concentrations by 42.5 -fold. There-
fore, it is possible that the weight-based VOR dosing of
4 mg/kg b.i.d. may have been responsible for the low break-
through (C. glabrata) infections in this report. These data
suggest that measuring and optimizing VOR levels may
have therapeutic consequence in preventing breakthrough
IFI in immunocompromised alloSCT patients. A prospec-
tive trial investigating targeted blood levels and dose-
adjustedVOR in high-risk alloSCTpatients is warranted.
Many studies have raised concern about an increased in-
cidence of zygomycosis infections following use of VOR in
alloSCT (13^15). However, the data are still limited, and no
conclusions can be made. One theory is that better support-
ive care, treatments such as VOR, and the use of more
potent immunosuppression allow prolonged survival of se-
verely immunocompromised patients, thus giving more
time for resistant fungal infections to develop. This retro-
spective study does not support an increased incidence
of zygomycosis. Only a large prospective randomized trial
can con¢rm the association of VOR to zygomycosis in-
fection.
There is no standard antifungal prophylaxis for pa-
tients experiencing chronic GVHD (cGVHD) and no pub-
lished reports onVOR prophylaxis during cGVHD. In this
report, a total of 6 of 39 patients developed late de¢nite or
probable IFI, but none of these patients developed fungal
disease while onVOR.The majority of subjects developed
GVHD following tapering of their immunosuppression
and after discontinuing VOR. As expected, cGVHD was
present before the development of late IFI in most pa-
tients, although the initiation of corticosteroids for other
reasons (disease relapse, possible autoimmune cytopenia)
was an important factor for IFI in 2 patients. A multi-
variate analysis was performed but failed to identify sig-
ni¢cant risk factors for late IFI, likely owing to the low
incidence of disease. Overall, these data suggest that
VOR is e¡ective prophylaxis for preventing late IFI in pa-
tients with cGVHD receiving intensive immunosuppres-
sion. As mold infections are a signi¢cant cause of late
morbidity and mortality in those with cGVHD, studies
are warranted to better de¢ne optimal antifungal therapy
during cGVHD (10).
In this cohort of patients, VOR was administered post
transplant for a median time of 128 days and was well tol-
erated. Common side e¡ects of VOR included visual distur-
bances and liver enzyme elevations. In 3 patients, the
abnormal liver tests occurred a mean of 8 days post trans-
plant and this was likely due to preparative therapy toxic-
ity.Three other patients discontinuedVOR because of liver
test abnormalities a mean of 81 days post transplant and all
had possible GVHD. Overall, the side e¡ects fromVORwere
not prohibitive and could be managed with dose interrup-
tions and/or dose reductions. VOR administration was
strictly prohibited during chemotherapy because of pre-
dictable drug^drug interactions. In addition, a 60% reduc-
tion in TAC dosing was required, thus o¡setting some of
the costs associated withVOR dosing.
In conclusion, VOR prophylaxis in alloSCT is safe and
e¡ective at preventing early and late IFI. Evaluating VOR
levels and optimizing VOR dosing may help to prevent
breakthrough fungal infection. LFTs and the QTc should
be monitored in patients receiving VOR as dose adjust-
ments may be required. The low incidence of zygomycosis
infections in this study does not support the premise that
VOR usage increases the incidence of resistant IFI. Al-
though most centers continue to use FLU as antifungal pro-
phylaxis,VORusage should be considered in centers where
the incidence of mold infection is increased. A randomized
clinical trial of FLU versus VOR prophylaxis in alloSCT is
ongoing and should further clarify the role of VOR as pro-
phylaxis (http://clinicaltrials.gov/ct/show/NCT00023530?
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order=1). A randomized trial of VOR versus posaconazole
prophylaxis in alloSCTwould also be of value.
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